These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28111984)

  • 1. Effects of meropenem exposure in persister cells of Acinetobacter calcoaceticus-baumannii.
    Gallo SW; Donamore BK; Pagnussatti VE; Ferreira CA; de Oliveira SD
    Future Microbiol; 2017 Feb; 12():131-140. PubMed ID: 28111984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acinetobacter baumannii displays inverse relationship between meropenem resistance and biofilm production.
    Perez LR
    J Chemother; 2015 Feb; 27(1):13-6. PubMed ID: 24621167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded Acinetobacter baumannii and Biofilm Architecture.
    Wang YC; Kuo SC; Yang YS; Lee YT; Chiu CH; Chuang MF; Lin JC; Chang FY; Chen TL
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4670-6. PubMed ID: 27216052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of persisters influenced by aeration in Acinetobacter calcoaceticus-baumannii.
    Donamore BK; Gallo SW; Abreu Ferreira PM; Sanchez Ferreira CA; de Oliveira SD
    Future Microbiol; 2018 Feb; 13():209-219. PubMed ID: 29302999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doripenem vs meropenem against Pseudomonas and Acinetobacter.
    Goyal K; Gautam V; Ray P
    Indian J Med Microbiol; 2012; 30(3):350-1. PubMed ID: 22885206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of the Acinetobacter calcoaceticus-A. baumannii complex to imipenem, meropenem, sulbactam and colistin.
    Dueñas Díez AI; Bratos Pérez MA; Eiros Bouza JM; Almaraz Gómez A; Gutiérrez Rodríguez P; Miguel Gómez MA; Orduña Domingo A; Rodríguez-Torres A
    Int J Antimicrob Agents; 2004 May; 23(5):487-93. PubMed ID: 15120728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii.
    Douraghi M; Ghalavand Z; Nateghi Rostami M; Zeraati H; Aliramezani A; Rahbar M; Mohammadzadeh M; Ghourchian S; Boroumand MA; Abdollahi A
    J Appl Microbiol; 2016 Aug; 121(2):401-7. PubMed ID: 27171885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Activity of tigecycline on planktonic and sessile cells of Acinetobacter baumannii].
    Can F; Kaya M; Bayindir Bilman F; Uncu H; Demirbilek M; Yazici AC
    Mikrobiyol Bul; 2009 Oct; 43(4):587-95. PubMed ID: 20084911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
    McCracken M; Mataseje LF; Loo V; Walkty A; Adam HJ; Hoban DJ; Zhanel GG; Mulvey MR;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest and time-kill assay.
    Pankey GA; Ashcraft DS
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):228-32. PubMed ID: 19150711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii.
    Kiffer CR; Sampaio JL; Sinto S; Oplustil CP; Koga PC; Arruda AC; Turner PJ; Mendes C
    Diagn Microbiol Infect Dis; 2005 Aug; 52(4):317-22. PubMed ID: 15936166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii.
    Ghazi IM; Grupper M; Nicolau DP
    Infect Dis (Lond); 2017; 49(11-12):831-839. PubMed ID: 28758820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of doripenem against Acinetobacter baumannii clinical isolates.
    Marti S; Sánchez-Céspedes J; Alba V; Vila J
    Int J Antimicrob Agents; 2009 Feb; 33(2):181-2. PubMed ID: 18977642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
    Lenhard JR; Thamlikitkul V; Silveira FP; Garonzik SM; Tao X; Forrest A; Soo Shin B; Kaye KS; Bulitta JB; Nation RL; Li J; Tsuji BT
    J Antimicrob Chemother; 2017 May; 72(5):1415-1420. PubMed ID: 28333347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interactions between colistin and meropenem against extensively drug-resistant and pandrug-resistant Acinetobacter baumannii isolated from ICU patients.
    Vourli S; Frantzeskaki F; Meletiadis J; Stournara L; Armaganidis A; Zerva L; Dimopoulos G
    Int J Antimicrob Agents; 2015 Jun; 45(6):670-1. PubMed ID: 25795317
    [No Abstract]   [Full Text] [Related]  

  • 16. Biofilm Formation Caused by Clinical Acinetobacter baumannii Isolates Is Associated with Overexpression of the AdeFGH Efflux Pump.
    He X; Lu F; Yuan F; Jiang D; Zhao P; Zhu J; Cheng H; Cao J; Lu G
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4817-25. PubMed ID: 26033730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of doripenem resistance with OXA-type carbapenemases in Acinetobacter baumannii isolates.
    Terzi HA; Atasoy AR; Aykan SB; Karakece E; Asık G; Ciftci IH
    Saudi Med J; 2016 Jan; 37(1):43-7. PubMed ID: 26739973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of polymyxin B and meropenem eradicates persister cells from Acinetobacter baumannii strains in exponential growth.
    Gallo SW; Ferreira CAS; de Oliveira SD
    J Med Microbiol; 2017 Aug; 66(8):1257-1260. PubMed ID: 28721845
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.
    Li X; Wang L; Zhang XJ; Yang Y; Gong WT; Xu B; Zhu YQ; Liu W
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6773-81. PubMed ID: 25182633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biofilm prevention concentrations (BPC) of minocycline compared to polymyxin B, meropenem, and amikacin against Acinetobacter baumannii.
    Beganovic M; Luther MK; Daffinee KE; LaPlante KL
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):223-226. PubMed ID: 30827805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.